This year’s NVGCT Annual Symposium took place on November 9th and 10th 2021 at the conference center De Werelt in Lunteren. We would like to thank all participants and sponsors for their contribution. For a summary of this event, click here.
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Rob Collin benoemd tot hoogleraar Moleculaire therapie voor erfelijke netvliesaandoeningen – Radboudumc
29 januari 2021
Met ingang van 16 januari 2021 is moleculair geneticus Rob Collin benoemd tot hoogleraar ‘Moleculaire Therapie voor Erfelijke Netvliesaandoeningen’ aan de Radboud Universiteit/het Radboudumc.
Gene therapy for a subtype of eye disease approved in the Netherlands
From 2021, patients suffering from RPE65-associated retinal disease will be able to be treated in three UMCs of the Netherlands.
https://www.radboudumc.nl/nieuws/2020/gentherapie-voor-zeldzame-oogziekte-vergoed
Scientists develop new gene therapy for eye disease | EurekAlert! Science News
Scientists from Trinity College Dublin have developed a new gene therapy approach that offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study, which involved a collaboration with clinical teams in the Royal Victoria Eye and Ear Hospital and the Mater Hospital, also has implications for a much wider suite of neurological disorders associated with ageing.
Source: Scientists develop new gene therapy for eye disease | EurekAlert! Science News